Featured Research

from universities, journals, and other organizations

Factors associated with rate of visual field change in patients with glaucoma identified

Date:
August 10, 2010
Source:
JAMA and Archives Journals
Summary:
Patients with glaucoma appear to have more rapid visual field change if they are older or if they have abnormal levels of anticardiolipin antibody (an antibody directed against a certain protein in the body), according to a new report. Reducing intraocular pressure -- the pressure within the eyeball -- modestly in these patients appears to ameliorate the rate at which they experience declines in visual field.

Patients with glaucoma appear to have more rapid visual field change if they are older or if they have abnormal levels of anticardiolipin antibody (an antibody directed against a certain protein in the body), according to a report posted online today that will appear in the October print issue of Archives of Ophthalmology. Reducing intraocular pressure -- the pressure within the eyeball -- modestly in these patients appears to ameliorate the rate at which they experience declines in visual field.

"Recent clinical studies and trials in glaucoma have advanced knowledge on risk factors for the disease. A recurring finding from these investigations is the importance of intraocular pressure for both the development of the disease in glaucoma suspects and progression in patients with established glaucoma," the authors write as background information in the article. "Evidence pertaining to risk factors and the effect of intraocular pressure reduction is derived almost exclusively from event-based or binary (progression vs. no progression) outcomes. In practical terms, it may be more beneficial to determine the effect of a risk factor or its modification on the rate of change such that the clinician can gauge the likelihood of lifetime visual disability with consideration of factors such as age, stage of the disease and life expectancy."

Balwantray C. Chauhan, Ph.D., of Dalhousie University, Halifax, Nova Scotia, Canada, and colleagues in the Canadian Glaucoma Study Group studied 216 patients with open-angle glaucoma, documenting several demographic, systemic and ocular parameters at the beginning of the study. The patients were all followed up with a standardized protocol for controlling intraocular pressure (targeting a reduction of 30 percent or greater) and then were re-examined every four months. Those who had confirmed progression of glaucoma as assessed by changes in their visual field received an additional 20 percent or greater reduction in intraocular pressure under the treatment protocol.

A total of 153 patients (70.8 percent) did not reach this end point of visual field deterioration during the study, 45 (20.1 percent) had one end point, 16 (7.4 percent) had two end points and two (.9 percent) had three end points. Having an abnormal level of anticardiolipin antibodies and being older were associated with a more rapid rate of visual change, but being female and having a higher follow-up intraocular pressure were not.

Patients who reached one end point and had an additional reduction in intraocular pressure experienced a slowing of their rate of visual field change. The magnitude of this amelioration may not have been clinically meaningful for some patients, but over 20 years, the difference would be significant. "In younger patients with more advanced damage, this difference is likely to be important," the authors write. However, there was no demonstrable effect of further reductions in intraocular pressure for patients with two or more end points.

This work was supported by the E.A. Baker Foundation, Canadian National Institute for the Blind, by the Glaucoma Research Society of Canada and by unrestricted grants from Allergan Canada, Merck Frosst Canada and Pfizer Canada.


Story Source:

The above story is based on materials provided by JAMA and Archives Journals. Note: Materials may be edited for content and length.


Journal Reference:

  1. Balwantray C. Chauhan et al. Canadian Glaucoma Study 3. Impact of Risk Factors and Intraocular Pressure Reduction on the Rates of Visual Field Change. Archives of Opthamology, DOI: 10.1001/archophthalmol.2010.196

Cite This Page:

JAMA and Archives Journals. "Factors associated with rate of visual field change in patients with glaucoma identified." ScienceDaily. ScienceDaily, 10 August 2010. <www.sciencedaily.com/releases/2010/08/100809161136.htm>.
JAMA and Archives Journals. (2010, August 10). Factors associated with rate of visual field change in patients with glaucoma identified. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2010/08/100809161136.htm
JAMA and Archives Journals. "Factors associated with rate of visual field change in patients with glaucoma identified." ScienceDaily. www.sciencedaily.com/releases/2010/08/100809161136.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins